Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses androgen receptor–resistance in prostate cancer.
Mark Stein, MD
Advertisement
Articles by Mark Stein, MD
Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses commercial tests for determining therapies for patients with prostate cancer.
Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses trials investigating the use of circulating tumor cells as biomarkers for patients with prostate cancer.
Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses the use of novel circulating biomarkers in the treatment of patients with prostate cancer.
Advertisement
Latest Updated Articles
Dr. Stein on Circulating Biomarkers in Prostate CancerPublished: November 19th 2016 | Updated:
Dr. Stein on Trials Investigating Biomarkers in Prostate CancerPublished: January 9th 2017 | Updated:
Dr. Stein on Commercial Tests to Determine Therapies for Prostate CancerPublished: January 19th 2017 | Updated:
Dr. Stein on AR-Resistance in Prostate CancerPublished: January 25th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5